Consulting agreement under which the company pays Dr. Homcy for consulting services.
| Officer | Age | In this role | Source |
|---|---|---|---|
|
Jason Coloma
Also a director
Chief Executive Officer and Director
|
50 | Not stated | |
|
Misbah Tahir
Chief Financial Officer
|
51 |
Since 2025
1 year
|
|
|
Harold S. Bernstein
President, R&D & CMO
Title from the Form 4 dated Oct 1, 2026
|
66 | Not stated | |
|
Courtney Phillips
General Counsel and Corporate Secretary
|
51 |
Since 2024
2 years
|
|
|
Atul Dandekar
CSBO
Title from the Form 4 dated Oct 29, 2026
|
55 | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 28, 2026 · updated by the 8-K of Aug 17, 2026
| Director | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|
|
Hervé Hoppenot
Board chair
|
2025
1 year
|
Not stated |
Nominating and Corporate Governance Committee · Chair
|
None stated | $738,726 | |
|
Jason Coloma
CEO
|
2019
7 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Neil Kumar
|
2026
this year
|
Not stated |
Audit Committee
|
None stated | Not stated | |
|
Jonathan Lim
|
2019
7 years
|
Not stated | None stated | None stated | $344,240 | |
|
Richard Scheller
|
2019
7 years
|
Not stated | None stated | None stated | Not stated | |
|
Nancy C. Andrews
|
2021
5 years
|
Not stated | None stated | None stated | Not stated | |
|
Charles Homcy
|
2018
8 years
|
Not independent | None stated | None stated | $602,065 | |
|
Daniel Spiegelman
|
2020
6 years
|
Not stated | None stated | Spruce Biosciences, Inc., vTv Therapeutics Inc. | $348,983 | |
|
Paula A. Johnson
Joined Aug 13, 2026
|
- | - |
nominating and corporate governance committee
|
- | - | |
|
Sophie Kornowski
Joined Aug 13, 2026
|
- | - |
audit committee
compensation committee
|
- | - | |
|
Neil Exter
Leaving at the meeting
|
Not stated | Not stated | None stated | None stated | $488,674 | |
|
Catherine Angell Sohn
Leaving at the meeting
|
Not stated | Not stated | None stated | None stated | Not stated |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Consulting agreement under which the company pays Dr. Homcy for consulting services.
Option to purchase 46,675 shares of common stock granted as additional consideration for consulting services.
Additional option to purchase 45,638 shares of common stock granted as additional consideration for consulting services.
Investors' Rights Agreement with certain stockholders, including director-affiliated entities holding more than 5%, granting registration rights.
Indemnification agreements with each director and executive officer, requiring indemnification and advancement of expenses.
Loading...